Potentiation of Estrogen Receptor Activation Function 1 (AF-1) by Src/JNK through a Serine 118-Independent Pathway
Weijun Feng,
Paul Webb,
Phuong Nguyen,
Xiaohong Liu,
Jiandong Li,
Michael Karin and
Peter J. Kushner
Metabolic Research Unit (W.F., P.W., P.N., P.J.K.) and
Department of Anatomy (J.L.) University of California San
Francisco, California 94143
Department of Pharmacology
(X.H.L., M.K.) University of California San Diego La Jolla,
California 92093
 |
ABSTRACT
|
---|
Estrogen receptor (ER) is activated either
by ligand or by signals from tyrosine kinase-linked cell surface
receptors. We investigated whether the nonreceptor Src tyrosine kinase
could affect ER activity. Expression of constitutively active Src or
stimulation of the endogenous Src/JNK pathway enhances transcriptional
activation by the estrogen-ER complex and strongly stimulates the
otherwise weak activation by the unliganded ER and the tamoxifen-ER
complex. Src affects ER activation function 1 (AF-1), and not ER AF-2,
and does so through its tyrosine kinase activity. This effect of Src is
mediated partly through a Raf/mitogen-activated ERK
kinase/extracellular signal-regulated kinase (Raf/MEK/ERK)
signaling cascade and partly through a MEKK/JNKK/JNK cascade.
Although, as previously shown, Src action through activated ERK
stimulates AF-1 by phosphorylation at S118, Src action through
activated JNK neither leads to phosphorylation of S118 nor requires
S118 for its action. We therefore suggest that the Src/JNK pathway
enhances AF-1 activity by modification of ER AF-1-associated proteins.
Src potentiates activation functions in CREB-binding protein (CBP) and
glucocorticoid receptor interacting protein 1 (GRIP1), and we
discuss the possibility that the Src/JNK pathway enhances the activity
of these coactivators, which are known to mediate AF-1 action.
 |
INTRODUCTION
|
---|
The action of estrogen receptor-
(hereafter, ER) is regulated
both by binding of ligand and by inputs from signal transduction
cascades. Binding of estrogen to ER frees it from a complex with heat
shock proteins and allows ER to bind estrogen response elements (EREs)
in the promoter region of target genes (for review see Ref. 1). ER then
stimulates transcription via the concerted action of the AF-1
activation function in its amino terminus and the hormone-dependent
activation function, AF-2, that lies within the ligand-binding domain
(LBD). The antiestrogen tamoxifen allows release from heat shock
proteins and ERE binding, but blocks AF-2 (reviewed in Refs. 1, 2).
Tamoxifen allows weak AF-1 activity, but in many cases this is
insufficient to increase gene expression (3). Other antiestrogens, such
as raloxifene and ICI 182,780 (ICI), allow neither AF-1 nor AF-2
activity (4, 5). Both activation functions work by recruiting a
coactivator complex to the promoter (reviewed in Refs. 1, 6, 7).
The complex contains a p160 protein, such as SRC-1(N-CoA1) (8, 9),
glucocorticoid receptor interacting protein 1 (GRIP1) (TIF2, N-CoA2)
(10, 11, 12), or p/CIP (AIB1, ACTR, TRAM-1, RAC3) (13, 14, 15, 16, 17), p300/CBP (CREB
binding protein) (9, 18, 19, 20), and p/CAF (21, 22, 23) (for review see Ref.
7). AF-1 binds the C terminus of the p160 component (24), whereas
estrogen-bound AF-2 binds tightly to a short
-helices with the
consensus LXXLL (the NR boxes) that are repeated several times within
each p160 (13, 25, 26, 27, 28, 29). The coactivator complex, once recruited,
stimulates transcription via its histone acetyl-transferase activity,
which is thought to remodel chromatin and allow access to the
transcriptional template, and by interactions with the basal
transcription machinery (15, 30, 31, 32).
ER activity is also stimulated by signaling pathways that are activated
when growth factors, such as epidermal growth factor (EGF) and
insulin-like growth factor I (IGF-I), bind their tyrosine kinase-linked
receptors. Growth factors are sometimes sufficient to activate ER in
the apparent absence of ligand (33, 34, 35, 36). More commonly, growth factors
synergize with ligand by enhancing AF-1 activity. EGF binding to the
EGF receptor results in sequential activation of Ras, Raf, MEK, and the
mitogen-activated protein (MAP) kinases ERK1 and ERK2, which
phosphorylate ER at serine 118 in the N-terminal domain and potentiate
AF-1 activity (36, 37, 38). Mutation of S118 to alanine blocks ER
phosphorylation by MAP kinases and potentiation of AF-1 action by
growth factors (36, 37, 38). Furthermore, the S118A mutation also reduces
basal phosphorylation of S118 by unspecified kinases (38) and decreases
basal AF-1 activity (39, 40). Phosphorylated ER AF-1 shows enhanced
binding to the p68 RNA helicase, which is thought to account for its
enhanced transcriptional activity (41). AF-1/GRIP1 interactions map to
the N-terminal region of the ER AB domain, which has not been
implicated in growth factor enhancement of AF-1 activity, and are
unaffected by mutations in serine 118 (24).
ER is likely to be subject to signal transduction inputs during normal
development and repair processes and may also be subject to abnormal
stimulation by such pathways in pathological states, such as cancer.
Many breast tumors exhibit elevated expression of growth factors such
as EGF, Her2/neu, IGFs, and their receptors (42, 43, 44, 45). Furthermore, more
than 80% of primary breast cancers show increased activity of the
nonreceptor Src tyrosine kinase activity compared with normal breast
tissue (Refs. 46, 47, 48, 49 ; reviewed in Ref. 50). Elevated Src activity leads
to activation of multiple signal transduction cascades (reviewed in
Refs. 51, 52, 53) that, in turn, activate both the ERK and JNK subgroups of
MAP kinases (for examples see Refs. 54, 55). Src activates ERKs
presumably via Ras and the Raf/MEK/ERK kinase cascade (see, for
example, Ref. 54). It also activates JNKs, presumably via Rac-1 and
related GTPases, and the sequential activation of the MEKK/JNKK/JNK
kinase cascade (56). In light of these reports we investigated whether
activated Src enhances ER action. We find that Src does so and that it
specifically enhances ER AF-1 activity via two independent mechanisms.
One involves phosphorylation at S118 via Src activation of the
Raf1-MEK-ERK pathway. The other is mediated by Src activation of the
MEKK-JNKK-JNK pathway, the target of which does not appear to be S118,
or even ER. We discuss the possibility that JNKs target one of the
several coactivators that associate with the ER.
 |
RESULTS
|
---|
Src Potentiates ER AF-1
Src activity in breast cancer cells and cell lines is often
elevated up to 30-fold (49). To examine the effects of elevated Src
activity on ER action, we transfected expression vectors for v-Src and
control vectors into HeLa cells along with expression vectors for ER
and an ERE responsive reporter gene (ERE:HSV-TK-CAT). v-Src is a viral
derivative of cellular Src (c-Src) which has at least 10-fold higher
kinase activity than c-Src. Figure 1A
shows that v-Src potentiated ER transcriptional activity by 2-fold in
the presence of 17ß-estradiol (E2), a primary
estrogen agonist activating both AF-1 and AF-2. V-Src also potentiated
ER activity in the absence of ligand by about 2-fold. More strikingly,
v-Src enhanced ER transcriptional activity in the presence of tamoxifen
(Tam), an ER ligand that inhibits AF-2 but allows AF-1 activity (3), by
about 15-fold. V-Src had no effect upon ER transcriptional activity in
the presence of ICI 182,780, an ER ligand that blocks the activities of
both AF-1 and AF-2 (3, 57, 58, 59). Thus, v-Src increases ER
transcriptional activity in the presence of estradiol and the absence
of ligand, but shows larger effects in the presence of tamoxifen. We
then examined v-Src effects upon ERG400V, an ER mutant that lacks
constitutive activity but is otherwise normal (60). Here, v-Src showed
modest potentiation of estrogen response and a much larger potentiation
of tamoxifen response. Thus, v-Src truly enhances the transcriptional
activity of the tamoxifen-ER complex above basal. Over the course of
this study, v-Src enhanced the overall levels of estrogen response by
between 50% and 4-fold, but consistently yielded larger enhancements
of tamoxifen response. Thus, v-Src increased the overall level of
tamoxifen response from a tiny percentage of estrogen response to
1540% of estrogen response.

View larger version (29K):
[in this window]
[in a new window]
|
Figure 1. v-Src Potentiates ER AF-1 Transcriptional Activity
A, Activity of an ERE-CAT reporter gene in HeLa cells transfected with
expression vectors for wild-type ER, the ER G400V derivative, and v-Src
and treated with estradiol (E2), tamoxifen (Tam),
and ICI 182,780 (ICI). B, Western blots were performed upon extracts of
cells that were transfected with different amounts of ER expression
vector, or control vector, ±transfected v-Src. The lower
panel shows transcriptional activation of the ERE responsive
reporter gene as a function of ER levels ± transfected v-Src. C,
Activity of the ERE reporter gene in HeLa cells transfected with an
expression vector for ER, the indicated amount of expression vector for
v-Src after treatment with tamoxifen (closed circles) or
vehicle (open boxes). Fold inductions were determined by
comparing the relative CAT activity in the presence of v-Src to that in
the absence of v-Src (set as 1-fold). D, Activity of the ERE-CAT
reporter gene in MCF-7 breast tumor cells that express endogenous ERs.
E, Activity of a reporter gene with five GAL4 response elements in
cells transfected with expression vectors for GAL4 fusion proteins to
the ER A/B region (GAL4-AB), to the ER ligand binding domain (GAL-LBD),
or to the herpes virus VP16 activation domain (GAL4-VP16) in the
presence or absence of cotransfected v-Src. Fold inductions were
determined as in Fig. 1C .
|
|
To confirm that v-Src effects upon ER activity could not be simply
explained by increases in ER levels, we performed Western blots on
extracts of cells that had been transfected with different amounts of
ER in the presence and absence of transfected v-Src. Figure 1B
shows
that the amount of ER increased as a function of transfected ER
expression vector in the absence of v-Src, and that v-Src increased ER
levels by about 3-fold. In parallel, v-Src gave much stronger
potentiation of ER action at the ERE responsive reporter gene, even at
ER levels that were optimal for estrogen and tamoxifen response (Fig. 1B
, lower panel). In particular, the ER activity obtained
with 3 µg of transfected ER and v-Src exceeded the ER activity
obtained with 10 µg of transfected ER and no v-Src, even though the
former contained lower amounts of ER protein. Thus, v-Src increases ER
transcriptional activity, especially in the presence of tamoxifen.
We then asked whether v-Src enhancement of ER activity might occur
under more physiological conditions. We first examined the amount of
v-Src required for enhancement of ER activity. Tamoxifen response
increased with as little as 300600 ng of transfected v-Src expression
vector (Fig. 1C
). We then examined v-Src action upon the ERE responsive
reporter in MCF-7 breast tumor cells, which express endogenous ER (Fig. 1D
). Here, ER showed significant constitutive activity, which was
further elevated by addition of estradiol but completely suppressed by
tamoxifen and ICI. In the presence of transfected v-Src, both the
constitutive and estrogen-dependent transcriptional activity were
modestly elevated and, once again, tamoxifen-dependent transcriptional
enhancement was strongly increased. Thus, v-Src enhances the activity
of the estrogen-ER and tamoxifen-ER complexes in breast cells, just as
it does in HeLa cells.
That the ER response to v-Src overexpression is more dramatic in the
presence of tamoxifen than in the presence of estrogen, and that there
is no response in the presence of ICI, suggests that ER AF-1 might be a
primary action target of v-Src. To investigate whether the target of
v-Src action was AF-1 or AF-2, we examined the effect of v-Src
overexpression upon the activity of a reporter gene with a promoter
containing a TATA box and multiple binding sites for the yeast GAL4
protein (5xGALRE-E1b-tata-LUC). This reporter was then activated with
the DNA binding domain of GAL4 fused to the ER A/B region containing
AF-1 [GAL4-ER(A/B)], to the ER LBD containing AF-2 [GAL4-ER(LBD)],
or to VP16 (GAL4-VP16). As shown in Fig. 1E
, v-Src potentiated the
GAL4-ER(A/B) transcriptional function approximately 30- to 40-fold, but
had only a minimal effect on GAL4-LBD or GAL4-VP16. Like v-Src action
upon the tamoxifen-liganded ER, v-Src potentiation of AF-1 activity
could be detected at optimal levels of transfected GAL4-ER(A/B)
expression vector (data not shown). Thus, v-Src strongly enhances ER
AF-1 activity. These observations are consistent with the strong
activation of the tamoxifen-bound ER by v-Src and confirm that the A/B
domain of ER, which contains AF-1, is the v-Src target.
Src Action upon ER Is Independent of Tyrosine 537
Some reports have suggested that Src directly phosphorylates ER at
tyrosine 537 (Y537) within the ER-LBD (61, 62, 63), although the
physiological significance of this effect is unclear. In fact, some
Y537 mutations were later shown to enhance ER activity in the absence
of hormone, by allowing ligand-independent interactions of ER AF-2 with
its target coactivators (64, 65, 66). To determine whether Y537
phosphorylation was required for v-Src action upon the ER, we examined
the effect of v-Src overexpression upon several ERs bearing mutations
at Y537. We chose Y537R, which shows similar constitutive activity to
wild-type ER, and Y537S and Y537F, which show either enhanced or
reduced constitutive activity, respectively.
Figure 2A
shows that ER and ER-G400V
elicited strong estrogen responses and weak tamoxifen responses from
the ERE responsive reporter. In parallel, ERY537R showed comparable
constitutive activity to wild-type ER, and ERY537S showed the expected
increase in constitutive activity, but both mutants showed similar
levels of activity to wild-type ER in the presence of estrogen and
tamoxifen. In the presence of v-Src, wild-type ER and each Y537 mutant
(Y537R and Y537S) showed a modest enhancement of transcriptional
activity in the presence and absence of estradiol and a larger
enhancement of transcriptional activity in the presence of tamoxifen.
Thus, v-Src effects upon the estrogen-ER complex, the unliganded ER,
and the tamoxifen-ER complex are all independent of a requirement for
ER phosphorylation at tyrosine 537. v-Src also enhanced estradiol and
tamoxifen activation in the presence of the ERY537F mutant, which lacks
constitutive activity (Fig. 2B
). This confirms that v-Src enhances the
activity of the tamoxifen-ER complex over basal, even when tyrosine 537
is mutated. We conclude that v-Src enhancement of ER activity occurs
through effects upon AF-1, and not through effects upon tyrosine 537 in
the ER-LBD.

View larger version (27K):
[in this window]
[in a new window]
|
Figure 2. Src Action upon ER Is Independent of Tyrosine 537
A, Activity of the ERE-CAT reporter was determined in the presence of
empty pSG5 expression vector, or expression vectors for ER, ERG400V,
ERY537R, and ERY537S, both in the presence of an empty expression
vector or an expression vector for v-Src. B, A similar experiment
performed with empty CMV expression vector or expression vectors for
wild-type ER and the Y537F derivative.
|
|
Src Kinase Activity Is Required for Potentiation of ER AF-1
To investigate whether elevated Src kinase activity itself, and
not some other feature of v-Src, leads to potentiation of ER action, we
examined the effect of various Src expression vectors and tyrosine
kinase inhibitors upon ER AF-1 activity. Wild type c-Src and
constitutively activated c-Src (Y527F) potentiated the activity of the
GAL-ER(A/B) fusion protein by 2
3- and 5-fold, respectively (Fig. 3
). The kinase-inactive mutant Src
(Y295K, Y527F), in contrast, was unable to enhance AF-1. Moreover,
enhancement of ER AF-1 by Src was blocked, and even reduced below basal
levels, by genistein and herbymicin A, two inhibitors of Src tyrosine
kinase activity (Fig. 3
). Control experiments indicated that both of
these inhibitors were without effect on GAL-VP16 (data not shown).
These results indicate that the intrinsic tyrosine kinase, and not
another feature of the v-Src molecule, mediates the enhancement of ER
activities. That the kinase inhibitors reduce AF-1 level below basal
may further suggest that endogenous Src tyrosine kinase activity might
underlie basal AF-1 activity.

View larger version (20K):
[in this window]
[in a new window]
|
Figure 3. Src Action on ER AF-1 Requires Src Tyrosine Kinase
Function
Shown is fold induction of the GALRE reporter gene activated by
GAL-ER(A/B) in the absence of Src (normalized to 1) and by c-Src, by
constitutively active c-Src [c-Src (Y527F)], by an inactive
derivative of c-Src [c-Src(K295R, Y527F)], or by v-Src in the absence
or presence of tyrosine kinase inhibitors (genistein or herbimycin).
The effect of the inhibitors on v-Src-enhanced and basal stimulation by
GAL-Elk1is shown in the inset.
|
|
Src Potentiates AF-1 through Both the Ras- Raf1-MEK-ERK and the
Rac-MEKK-JNKK- JNK Pathways
Src tyrosine kinase might affect AF-1 either directly or
indirectly through the numerous signal transduction cascades that Src
is known to initiate. While Src is generally associated with the plasma
membrane, and ER is generally nuclear, these locations are not rigid.
In particular, there are reports of ER associated with the cell surface
(67, 68). Thus, there is nothing a priori to exclude the
possibility that Src might directly phosphorylate the ER AF-1 domain.
We therefore tested whether a glutathione-S-transferase
(GST)-ER(A/B) fusion protein was a substrate for activated c-Src
kinase. GST-ER(A/B) was efficiently phosphorylated by activated ERK2
MAP kinase, consistent with other studies (37), but not by activated
c-Src kinase (Fig. 4A
). Thus, ER is not a
direct substrate of Src. We infer that Src must activate ER AF-1
indirectly through phosphorylation cascades.

View larger version (29K):
[in this window]
[in a new window]
|
Figure 4. v-Src Activates AF-1 through ERK and JNK MAP
Kinases
A, The ER A/B domain is a target for ERK but not Src kinase. Assay of
kinase activity using purified Src and ERK kinases, a peptide Src
substrate (amino acids 620 of cdc-2), PHAS-I (a peptide ERK
substrate), and purified GST-ER(A/B) fusion protein, as indicated. B,
v-Src action on AF-1 is partly blocked by dominant negative Ras
[Ras(S17N)], Raf1 [Raf(1257)], MEK [MEK(K97R)], or the PD 98059
compound that blocks activation of ERK MAP kinases. Induction of a
GALRE reporter gene activated with GAL-ER(A/B) and v-Src in the
presence of the indicated dominant negative or drug inhibitor.
Inset on right shows the expected complete blockade of
EGF action on Elk-1 by the dominant negatives and PD compound. C, v-Src
action on AF-1 is also blocked by dominant negative Rac [Rac(S17N)]
or MEKK [MEKK(K432M)]. An assay similar to B of reporter gene
response to Src in the presence of the indicated dominant negative
inhibitor. D, TNF and Src action on AF-1 is blocked by dominant
negative JNKK(K116R). Induction of the GALRE reporter gene activated by
GAL-ER(A/B) in HeLa cells cotransfected with dominant negative JNKK
[JNKK(K116R)] as indicated. After 20 h incubation, the cells
were treated with TNF for 1 h or transfected with v-Src
expression vector, as indicated, and then incubated for 6 h before
assay. E, ERK2 and JNK1, but not p38, cooperate with Src to activate
AF-1. Induction of the GALRE reporter gene activated by GAL-ER(A/B) in
the presence of activated Src and elevated ERK2, JNK1, or p38 as
indicated.
|
|
Because Src is known to cause MAP kinase activation, and the well known
pathway of Ras, Raf-1, MEK, and ERK activation enhances AF-1 activity
through serine 118 phosphorylation, we asked whether v-Src might
enhance ER activity by initiating the Raf-1/MEK/ERK cascade. We first
examined the effect of various inhibitors of this pathway upon EGF
stimulation of the transcription factor ELK-1, which responds even more
dramatically to EGF than does the ER. As shown in Fig. 4B
, left, each of these reagents nearly abolished the EGF
activation of a GAL-Elk1 fusion protein. PD 98059, a specific inhibitor
of MEK activation (69), also blocked EGF activation of GAL-Elk1. Thus,
these inhibitors work effectively to block transcription mediated by
the ERK pathway in these transfected cells. In contrast, only modest
(2040%, shown) decreases in v-Src effects on GAL-ER (A/B) were
detected. Even high levels of transiently transfected expression
vectors for each dominant negative protein produced no more than
3040% inhibition of Src action (data not shown). Similar modest
inhibition was obtained with PD 98059. These results indicate that Src
potentiation of ER AF-1 is only partly mediated by the Ras/Raf/MEK/ERK
pathway and suggest that another pathway must also be involved.
Because the Rac-MEKK-JNKK-JNK pathway is also activated by v-Src, we
then asked whether this pathway might mediate v-Src effects upon the
ER. Dominant negative Rac(S17N) or MEKK1(K432M), strongly inhibited
v-Src activation of ER AF-1 (Fig. 4C
). In a separate experiment a
vector for dominant negative JNKK4(K116R) eliminated the induction
mediated by short-term exposure to v-Src expression or stimulation of
the endogenous Src/JNK pathway treatment with the cytokine tumor
necrosis factor-
(TNF
) (Fig. 4D
). These observations indicate
that the route from Src to AF-1 proceeds through both the Ras-Raf-MEK
and the Rac-MEKK-JNKK pathways and that the ERK and JNK kinases are the
true effectors of Src action.
The role of the ERK and JNK kinases was then confirmed by examining the
effect of elevated expression of these kinases on Src action.
Overexpressed JNK1 and ERK2 synergized with v-Src to activate ER AF-1
(Fig. 4E
). Neither JNK nor ERK was sufficient to enhance AF-1 activity
in the absence of v-Src, suggesting that both required inputs from
upstream kinase cascades to enhance AF-1 activity. In contrast,
overexpression of another MAP kinase, p38, which is also activated by
JNKK1 (70), inhibited, rather than synergized with, the v-Src
activation of ER AF-1. While the mechanism of this dominant negative
effect of p38 is unknown, the fact that p38 acts as a dominant negative
indicates that p38 does not mediate Src activation of AF-1. In summary,
these studies indicate that the route from Src to AF-1 proceeds through
both a Ras-Raf-MEK-ERK and a Rac-MEKK-JNKK-JNK pathway.
Src Potentiates AF-1 Both by ERK-Mediated Phosphorylation of S118
and by a JNK- Mediated, S118 Independent, Pathway
As noted previously, activation of the Ras-Raf-MEK-ERK pathway
leads to phosphorylation of ER S118 by ERKs. We therefore investigated
whether S118, or the nearby S104 and S106, played similar roles in Src
activation of AF-1. We first examined the effect of S118 mutations to
glutamic acid (E), which mimics the negative charge of phosphorylated
serine and allows stronger ER AF-1 binding to p68 RNA helicase (36, 41), or arginine (R), which blocks S118 phosphorylation and shows
robust inhibition of ER AF-1 activity (71). As expected, ERS118E showed
a slight increase in tamoxifen response relative to ER, and ERS118R
showed no tamoxifen response (Fig. 5A
).
In parallel, transfected v-Src gave a much stronger enhancement of
tamoxifen response, suggesting that the increased negative charge of
the ER-S118E mutant was insufficient to mimic the enhancement of AF-1
activity that is obtained with v-Src. Furthermore, ERS118E-dependent
tamoxifen responses were still strongly enhanced by v-Src, and ERS118R
only reduced the overall level of tamoxifen response in the presence of
v-Src by about 50%. v-Src also potentiated the tamoxifen responses
that were obtained in the presence of an ERS118A mutant (data not
shown). Together, these results suggest that v-Src potentiation of AF-1
activity is partially insensitive to mutation of S118. Mutation of S118
to alanine also decreased the ability of v-Src to potentiate
GAL-ER(A/B) by 20 to 40% (Fig. 5B
and data not shown). There was no
further decrease in AF-1 activity when all three serines were mutated
to alanine (S104, 106, 118A). Thus, v-Src enhancement of isolated AF-1
is also partially insensitive to mutation of the AF-1 phosphorylation
sites.

View larger version (32K):
[in this window]
[in a new window]
|
Figure 5. Src-Activated ERKs, but not JNKs, Require S118 in
the A/B Domain to Activate AF- 1
A, Src potentiation of AF-1 is in part independent of S118. Induction
of the ERE responsive reporter gene activated by ER, or ERS118E and
ERS118R, with and without transfected v-Src. B, Induction of the GALRE
reporter gene activated by GAL-ER(A/B) or the indicated mutant thereof,
with v-Src. v-Src induction of wild-type GAL-ER(A/B) was set as 100%.
C, Src activation of AF-1 that is independent of S118 is resistant to
PD 98059, the ERK pathway inhibitor. Src effects are shown as fold
induction of reporter gene activity. D, Src potentiation on ER(A/B)
with mutations in S118 serine cluster cooperates with JNK but not ERK
kinases. Induction of the GALRE reporter gene activated with
GAL-ER(A/B) S118, v-Src, and vectors for JNK1 or ERK2, as indicated.
|
|
It is noteworthy that Src has a major effect on AF-1, even in
the presence of the triple serine mutation. To test whether this effect
is mediated by the non-ERK (that is, JNK) part of the Src-AF-1 pathway,
we examined Src activation of wild-type and triple mutant GAL-ER(A/B)
in the presence of PD 98059. This inhibitor reduced Src potentiation of
AF-1 activity by about 50%, as did the mutation of the three serines
(Fig. 5C
). However, PD 98059 had no effect on the residual Src
activation of the triple serine mutant. This result indicates that the
portion of the Src effect that is independent of S118 phosphorylation
is also ERK independent. Because JNK activation is not blocked by PD
98059 (Ref. 69 and data not shown), we infer that the
serine-independent portion of AF-1 activation is likely to be the
portion that is mediated by JNKs.
To examine the role of JNKs more directly, we examined the ability of
Src and overexpressed JNK to cooperate in AF-1 activation. As shown in
Fig. 5D
, v-Src and JNK cooperated to enhance the activity of GAL-A/B
S118A mutant even more strongly than v-Src alone. Thus, the Src-JNK
pathway enhances AF-1 activity in a manner that is independent of
phosphorylation at S118. Surprisingly, ERK1 now specifically inhibited
v-Src action at the GAL-A/B S118A mutant, much as p38 inhibited v-Src
action upon wild-type AF-1 (Fig. 4E
). Again, we do not have a ready
explanation for this effect but speculate that transfected ERKs could
inhibit other second messenger inputs to AF-1 and that this effect is
only detectable when their stimulatory effect upon ER AF-1 activity is
abolished. Nonetheless, taken together, our results suggest that v-Src
enhances AF-1 activity via two independent pathways, one that involves
ERKs and targets the AF-1 serine cluster and one that involves JNKs and
is independent of the serine cluster.
Src Activates Two Separate Subdomains of AF-1 That Show
Differential Sensitivity to Inhibitors of MAP Kinases
AF-1 is complex, and it has been suggested that AF-1 is comprised
of independent subdomains (39, 57, 72). We therefore tested some of
these candidate subdomains for response to Src. We transfected
expression vectors for ERs with specific deletions of the N-terminal
(AB) domain into HeLa cells and examined whether they would elicit a
tamoxifen response from the ERE-chloramphenicol acetyltransferase (CAT)
reporter gene in the presence or absence of cotransfected v-Src (Fig. 6A
). As expected, v-Src enhanced the
tamoxifen response obtained with wild-type ER by about 8-fold and
showed no effect upon an ER truncation that lacked the A/B domain
(
AB, 185). Transfected v-Src also enhanced the tamoxifen response
obtained with an ER truncation that contained amino acids 1129 by
7-fold. This truncation contains all of the ER sequences that are
required for AF-1 activity in HeLa cells (57), so this result
underscores the notion that v-Src acts upon AF-1. Transfected v-Src
enhanced the tamoxifen responses obtained with ERs bearing either the
N-terminal (amino acids 194) or C-terminal (amino acids 101185)
AF-1 subdomains by about 5- fold. Furthermore, Src responsiveness of
the C-terminal AF-1 subdomain was lost when the region from 101 to 117,
which contains the serine cluster, was deleted (117). Together, these
observations indicate that v-Src targets two separate subdomains in
AF-1. One lies between amino acids 194, and a second lies between
amino acids 101129, which overlaps the serine cluster. Although the
role of the serine cluster as a target of second messengers is well
established, this is the first direct indication that the N-terminal
region of AF-1 (amino acids 194) contributes to second messenger
stimulation of AF-1 activity.

View larger version (31K):
[in this window]
[in a new window]
|
Figure 6. Src Potentiates Transcription from Two Separable
Subdomains of AF-1
A, Fold induction that v-Src elicits from the ERE reporter gene
activated by the indicated ER derivative in the presence of tamoxifen.
B, The sensitivity of v-Src enhancement of tamoxifen response to PD
98059 was determined in the presence of the indicated ER derivative in
the presence of tamoxifen. All values (after subtraction of
backgrounds) were normalized to that obtained in the presence of fully
wild-type ER, which was set at 100%.
|
|
Control transfections revealed that PD 98059 completely failed to
inhibit the activity of the ER truncation that only contained the
N-terminal AF-1 subdomain (amino acids 194, Fig. 6B
). Thus, v-Src
action upon the N-terminal AF-1 subdomain does not proceed through MAP
kinase activation, which implies that v-Src action upon this region
proceeds through JNK kinases.
Activated JNKs Do Not Phosphorylate the AF-1 Domain, Suggesting an
Indirect Mode of Action
The above studies indicate that Src activates AF-1 through at
least two pathways, one of which is mediated through JNK and does not
require S118. To investigate whether JNK might phosphorylate another
site within AF-1, we tested the ability of JNKs extracted from cells
that had been treated with TNF
, the proinflammatory cytokine and
activator of Src/JNK (70), for their ability to phosphorylate the AF-1
domain in vitro. Activated JNKs were able to efficiently
phosphorylate a c-Jun substrate in vitro (Fig. 7
, top) but were unable to
phosphorylate an AF-1 substrate, even though this substrate had been
efficiently phosphorylated by activated ERK as shown earlier (Fig. 4A
).
We conclude that activated JNKs do not directly phosphorylate the ER
AF-1 domain.

View larger version (29K):
[in this window]
[in a new window]
|
Figure 7. ER(A/B) Is Not Phosphorylated by JNK1 in
Vitro
GST-cJun or GST ER(A/B) was in vitro phosphorylated by
immunopurified JNK1 kinase extracted from HeLa cells treated with
TNF (a Src/JNK activator) and analyzed on 10% SDS-PAGE with
autoradiography. Control experiments (see Fig. 3 ) indicate that
GST-ER(A/B) is a good substrate for ERKs.
|
|
Src Can Potentiate AF-1 in Conditions Where AF-1 Is Mediated by
the GRIP1/CBP Complex
Our results show that Src stimulates ER AF-1 activity through JNK
kinases and that the JNKs do not phosphorylate the AF-1 domain. This
suggests that the action of the JNK pathway on AF-1 may be mediated by
phosphorylation of another protein that mediates ER activity. Basal
AF-1 activity is mediated by a complex of a p160 such as GRIP1, along
with p300/CBP (24). The essential contact for this action is between
the N-terminal subdomain of AF-1 and the C-terminal domain of GRIP1. We
therefore asked whether v-Src enhanced AF-1 under conditions in which
AF-1 is itself enhanced by overexpression of GRIP1 and CBP.
We first cotransfected expression vectors for GRIP1 or CBP, along with
vectors for GAL-AF-1 and v-Src, and asked whether the coactivators
would potentiate v-Src action on the GALRE:luc reporter gene.
Overexpression of GRIP1 further enhanced v-Src potentiation of ER AF-1
(7- to 9-fold, Fig. 8A
, left).
CBP also slightly increased Src effects on AF-1, similar to its action
on basal AF-1 (24). Thus, v-Src synergizes with overexpressed GRIP1 and
CBP, suggesting that Src activation of AF-1 can occur when AF-1
activity is mediated by contacts with GRIP1 and CBP. We further
examined whether the S118-independent and PD 98059-resistant component
of Src action also synergizes with GRIP1. GRIP1 synergized with v-Src
to activate GAL-AF-1 with the triple serine mutation S104, 106, 118 A
(Fig. 8A
, right) both with and without PD 98059. We conclude
that the S118-independent and PD-resistant component of the Src pathway
of AF-1 potentiation is active when AF-1 is mediated by the p160
coactivator GRIP1.

View larger version (21K):
[in this window]
[in a new window]
|
Figure 8. Src/JNK Potentiates ER AF-1 Mediated by GRIP1 and
CBP
A, Elevated GRIP1 or CBP cooperate with Src in activation of AF-1.
Left panel shows induction of the GALRE reporter gene
activated with ER-GAL(A/B) and the effects of transfected v-Src GRIP1
or CBP as indicated. Right panel shows the substantial
effects of GRIP1 on v-Src potentiation of the triple serine ER-AF-1
mutant even in the presence of PD 98059 as indicated. B, A mutant of
GRIP1 deficient for mediating basal AF-1 acts as a partial dominant
negative for Src action on AF-1. Response of the reporter gene to v-Src
in the presence of elevated amounts of the indicated derivative of
GRIP1. GRIP1(11,121) is missing amino acids 1,1221,462 and does not
bind to ER(A/B) or mediate AF-1 action in the absence of Src. C, CBP
and GRIP1 activation functions are potentiated by Src. Activity of the
GALRE:luciferase reporter gene activated by GAL4 fusions to CBP or
GRIP1 as indicated and cotransfected with expression vector for v-Src.
|
|
As noted above, both AF-1 and AF-2 recruit the p160-CBP complex, but
the two ER domains contact different surfaces on the coactivators. AF-1
contacts the C-terminal domain of GRIP1 (24), whereas AF-2 contacts one
of the multiple p160 NR Boxes, which are located in the middle portion
of GRIP1 (13, 26, 27, 28, 29). Thus, deletion of the C terminus of GRIP1
prevents AF-1 activity without affecting AF-2. To test whether
AF-1/GRIP1 contacts were needed for v-Src enhancement of AF-1, we
overexpressed a C-terminal deletion of GRIP1 (11,121 aa), which lacks
the site for AF-1 binding (24). The GRIP1 mutant missing the C terminus
failed to cooperate with v-Src to enhance AF-1 and reduced activation
by v-Src (Fig. 8B
). Similar observations were also obtained in the
presence of tamoxifen-activated ER (data not shown). Thus, the
C-terminus-deleted GRIP1 has a dominant negative effect on Src
activation of AF-1. Taken together, these observations confirm
that Src can potentiate AF-1 under conditions where AF-1 activity is
mediated by contacts with the GRIP1 C terminus. It may also indicate
that Src activation of AF-1, like basal AF-1 activity, requires the
GRIP1/CBP complex or its functional equivalent.
Src Potentiates CBP and GRIP1 Activation Functions
The above studies suggest that Src potentiation of ER AF-1 is
compatible with circumstances in which AF-1 activity is mediated by
contacts with GRIP1 and CBP, but the studies are neutral as to whether
Src affects the activities of GRIP1 and CBP or some other target. To
gain insight into this latter question, we investigated how Src
affected the transcriptional activation functions of CBP and GRIP1.
GRIP1 or CBP fused to the DNA binding domain of GAL4 activate
transcription when they are tethered to the GALRE reporter gene (Fig. 8C
). Cotransfection of v-Src greatly increased both the transcriptional
activity of CBP and GRIP1. We conclude that v-Src has the potential to
change the activities of the GRIP1/CBP coactivator complex. Below we
discuss the possibility that this complex may be one of the candidates
for a Src/JNK target (see Discussion).
 |
DISCUSSION
|
---|
We were encouraged to investigate whether elevated Src potentiates
ER action by two observations. First, in addition to estrogen, ER
activity is also stimulated by signaling cascades initiated at tyrosine
kinases. Second, Src tyrosine kinase activity is often elevated in
breast cancers, whose proliferation is stimulated by ER activation. Our
studies indicate that expression of constitutively active forms of Src
or cell stimulation with the cytokine TNF
, both of which lead
to JNK activation (56, 73), enhances activation of reporter gene
expression by the estrogen-ER complex and powerfully enhances the
otherwise weak regulation by the tamoxifen-ER complex. These effects
are observed both in transiently transfected HeLa cells and in MCF-7
breast cells that express endogenous ERs. Src action upon the ER is
mediated through a robust activation of the ER AF-1 function. This is
seen most easily when the AF-1 region is removed from the remainder of
the ER and fused to a heterologous DNA binding domain from the yeast
GAL4 protein. Src action did not require the integrity of tyrosine 537
in the ER-LBD, which has been reported to be directly phosphorylated by
Src (61, 62, 63). Src tyrosine kinase activity is required for its action
upon AF-1, as mutations and drugs that inactivate the kinase block the
ability of Src to stimulate ER activity. Thus, taken together, our
results suggest that elevated Src kinase activity results in elevated
ER AF-1 activity.
The mechanism of Src enhancement of AF-1 activity is unusual. Previous
studies have demonstrated that growth factors enhance AF-1 activity via
a signal transduction pathway that is mediated by Ras, Raf, MEK, and
the ERK kinases. We therefore expected that Src stimulation of ER
activity might proceed through a similar pathway. However, transfection
of dominant negative Ras, Raf1, and MEK mutants, or treatment of cells
with PD 98059, which blocks Raf1 inputs to MEK, only partially
inhibited Src potentiation of AF-1. This suggested that Src also
enhanced AF-1 activity via a second pathway and, indeed, dominant
negative versions of Rac, MEKK, and JNKK also inhibited Src enhancement
of AF-1 activity. Src cooperates both with overexpressed ERK and
overexpressed JNK to generate even higher AF-1 activity. Thus, the Src
pathway leading to potentiation of AF-1 proceeds through JNKs and
through ERKs.
Although the pathway from Src to enhancement of AF-1 activity clearly
runs through Rac/MEKK/JNKK and JNKs, it is unclear how the JNKs bring
about the enhancement of AF-1 activity. One possibility is that the
JNKs directly phosphorylate the AF-1 domain and thereby modify its
function, as previously shown for transcription factors c-jun (74, 75)
and Elk-1 (76). Our in vitro studies weigh against this
possibility, as they indicate that JNKs fail to bind AF-1 (data not
shown) and that they also fail to phosphorylate the ER A/B domain
in vitro. Although it is possible that these failures
reflect a requirement for an accessory protein not supplied in
vitro, it is most likely an indication that the JNKs cannot
efficiently phosphorylate the AF-1 domain, as activated JNKs require no
accessory proteins to phosphorylate other substrates (75, 77, 78). Our
in vivo studies also suggest that JNK action is independent
of direct ER phosphorylation. The major site of phosphorylation in the
AF-1 region is S118, and mutation of this residue to alanine blocks
AF-1 phosphorylation and enhancement of AF-1 activity by EGF, activated
Ras, and other activators of ERK kinases. JNKs do not activate AF-1 via
phosphorylation at S118. Replacement of S118 with alanine only partly
reduces Src stimulation of AF-1 activity, and the residual activation
is mediated through an ERK-independent pathway. We infer that this
residual action is due to Src-activated JNK and this has been confirmed
with overexpressed JNKs. In addition, the Src-to-JNK cascade
targets at least two subdomains within AF-1, from amino acids 194,
and 101129. The first of these domains contains no potential sites
for JNK phosphorylation. Furthermore, replacement of the serine
cluster, including the MAP kinase phosphorylation site (S118), has no
effect on the response of AF-1 to JNK activation.
How does Src-activated JNK enhance AF-1? One attractive possibility is
that activated JNKs target a protein that, itself, affects AF-1 action.
Recent studies indicate that AF-1 works by recruiting p160/CBP
coactivators by means of a direct contact between AF-1 and the C
terminus of the p160 (24). We have confirmed that Src enhancement of
AF-1 activity can also occur in the presence of overexpressed GRIP1 and
CBP, and that this enhancement requires the C terminus of GRIP1. Thus,
one possibility is that the AF-1 mediating activities of the p160/CBP
complex are the target for JNK. Accordingly, v-Src was able to enhance
the transcriptional activity of both GRIP1 and CBP when they were
directly tethered to DNA. One obvious question is that if, indeed,
v-Src does enhance the activity of the GRIP1/CBP complex, and given
that both AF-1 and AF-2 work by binding a GRIP1/CBP complex, then why
would v-Src preferentially enhance AF-1 activity? We have previously
shown that the AF-1 and AF-2 functions of different nuclear receptors
both bind to p160s, but bind to different surfaces and require
different transcriptional outputs (24, 79). Thus, v-Src could
preferentially affect AF-1 activity by preferentially affecting a
subset of p160 transcriptional inputs or outputs that are required for
AF-1 action.
We stress that the sole positive evidence for Src/JNK targeting of the
coactivator complex is that Src potentiates the transcriptional
activation functions of both GRIP1 and CBP when they are fused to GAL4
and tethered to a promoter. This experiment is only suggestive.
While JNKs might phosphorylate GRIP1 itself, or another component of
the complex (Fig. 9
), there are other,
equally likely, possibilities. For example, JNKs might phosphorylate
and modify the activities of corepressors that are suspected of
modulating AF-1 action. Exploratory studies are underway to examine
these and other possibilities.

View larger version (20K):
[in this window]
[in a new window]
|
Figure 9. Pathways of v-Src Stimulation of ER(A/B)
Transcriptional Activity
One pathway leads from Src through Ras, Raf, MEK, and ERKs and results
in phosphorylation of the ER(A/B) on S118. The second pathway leads to
Rac, MEKK, JNKK, and JNKs. JNKs do not phosphorylate S118. Among many
possibilities JNKs may target coactivators that mediate AF-1 activity.
This is indicated by an arrow from JNK to coactivators.
That it is merely a possibility is indicated by the question
mark.
|
|
Finally, we speculate that Src enhancement of AF-1 may have
consequences for cellular responses to estrogen. Breast cancer samples
and cell lines almost invariably have elevated Src tyrosine kinase
activity (50). Some of those tumors and cell lines also express ER and
are stimulated to grow by estrogens. In such cases, ER is
believed to enhance proliferation by enhancing the expression of target
genes encoding regulators of proliferation. We showed here that
overexpression of v-Src leads to increases in ER transcriptional
activity in breast cells, and that this effect occurs in the presence
of estradiol, the absence of hormone and, most strikingly, in the
presence of tamoxifen. Thus, increases in Src kinase activity could,
via stimulation of ER transcriptional potency, enhance the ability of
ER to induce cellular proliferation in breast cancer and breast cancer
cell lines. Moreover, increased Src kinase activity could also lead to
increased tamoxifen agonist activity, which might play a role in the
development of tamoxifen resistance. We note that the tyrosine kinase
inhibitors genistein and Herbimycin A inhibit cellular proliferation in
response to estrogen (80, 81, 82, 83). Both of these inhibitors block Src
activity in breast cancer cells and also inhibit Src effects upon ER
AF-1. Thus, it is conceivable that both drugs could inhibit
estrogen-induced proliferation via inhibition of Src effects upon the
ER. Taken together, our results suggest that it is important to
investigate the relationship of Src activity and ER action in breast
cancer and during tumor progression.
 |
MATERIALS AND METHODS
|
---|
Mammalian Reporter Genes and Expression Vectors
EREII-HSV-TK-CAT, a reporter gene containing two vitellogenin
EREs upstream of the herpes simplex virus TR proximal promoter
(-109/+45), has been previously described (84). The GAL4 responsive
reporter gene GK1 contains five GAL4 response elements upstream of a
minimal adenovirus E1b promoter that has been previously described
(85).
ER expression vectors pSG5-ER, pSG5-ERG400V have been described
previously (86). pSG5-ER
(A/B), and
1100,
1116,
130184, and
95184 have been described previously (57).
pSG5-GAL4, -GAL4-ER(A/B), -GAL4-ER(LBD), -GAL4-VP16 expression vectors
have been described (57, 87). The pSG5-ERY537R, Y537S mutants were
obtained from Dr. G. Greene, University of Chicago. The pCMV-ERY537F
mutant was obtained form Dr. B. Katzenellen-bogen, University of
Illinois. The pSG5-GAL4-ER(A/B) mutants in which each the
phosphorylation sites at serine (S) 104, S106, S118, were mutated to
alanine (A) were created by synthesizing double-stranded
oligonucleotides that encode the mutant sequence and using Quick Change
Site-directed Mutagenesis Kits (Stratagene, La Jolla, CA).
The mutated sequences were verified by DNA sequencing using Sequenase
Kits (Stratagene). The GAL-4-ER(A/B) mutant containing the
triple phosphorylation site mutation (S104, 106, 118A) was made by
multiple rounds of mutagenesis.
Many signal transduction molecule expression vectors were kindly
provided as follows: pCMV-v-Src (Dr. M. Bishop, University of
California, San Francisco, CA); pCMV-c-SrcRF(K295R,Y527F) and
pCMV-c-Src (Dr. Joan Brugge, Ariad Pharmaceuticals, Inc., Cambridge,
MA); Constitutively activated pCMV-c-Src (Y527F) (Dr. Tony Hunter, Salk
Institute for Biological Studies, La Jolla, CA); dominant negative
pcDNA3-Rac1(S17N) and -Raf(1257) (Dr. H. Goldberg, University of
Toronto, Toronto, Ontario, Canada); pCMV-Flag-p38 (Dr. Roger Davis,
University of Massachusetts Medical Center, Boston, MA). Dominant
negative Ras(S17N), MEK(K97R), pSR
-JNKK(K116R), MEKK(K432M),
HA-JNK1, and HA-ERK2 have been described previously (56). Coactivator
expression vector pCMV-CBP was a gift from Dr. M. Rosenfeld (University
of California San Diego, La Jolla, CA). pSG5-GRIP1 has been
previously described (29).
Cell Culture and Transfection
HeLa cells were maintained and transfected as previously
described (86). Briefly, around 70% confluent HeLa cells were
transfected with 5 µg of (ERE)2-TK-CAT or 5x
GAL4-Luc reporter gene, 1 µg ß-galactosidase plasmid, 1 µg ER
expression vector, and other coactivator and signal molecule expression
vectors (2 µg) as indicated in the figure legends. After 20 h
incubation, cells were lysed and CAT, LUC, and ß-galactosidase assays
were performed using standard methods. The ß-galactosidase activity
was used to correct the variations of transfection efficiency in CAT
and LUC activities. The hormones (10 nM estradiol, ICI, and
5 µM tamoxifen) and kinase inhibitors [300
µM genistein (Sigma, St. Louis, MO), or 1
µM herbimycin A (Sigma), and 100 µm PD
98059 (Calbiochem)] were added immediately after
transfection. CAT and LUC activities represented the averages from
triplicate wells with less than 20% deviation. Experiments were
repeated at least three times.
Western Blots
HeLa cells were transfected with ER and v-Src expression
vectors, or empty control vectors, and allowed to stand overnight. Half
were prepared for Western blot analysis, and the remaining half was
used for standard CAT and ß-galactosidase assays. The following day,
the transfected cells were washed in cold PBS and treated with 1 ml of
luciferase lysis buffer on ice for 5 min. The lysate was scraped off
the dish, transferred to Eppendorf (Madison, WI) tubes,
and pelleted in an Eppendorf microfuge for 15 min at 4 C.
Protein contents were determined and 15 µg of cell proteins were
separated on a 10% SDS-polyacrylamide gel and transferred to a
premoistened Immuno-Blot polyvinylidene difluoride
membrane (Bio-Rad Laboratories, Inc. Hercules CA),
overnight at 90 mA, 30V, using a standard transfer apparatus. After
transfer, the membrane was incubated at room temperature in 5% nonfat
milk in PBS-T (1xPBS, 0.1% Tween-20) for 1 h, and washed twice
in PBS-T for 10 min. The primary anti-ER antibody (HC-20, Santa Cruz Biotechnology, Inc.,, Santa Cruz, CA) was diluted 1:2,000
in PBS-T and incubated with the membrane for 1 h, followed by
PBS-T washes, once for 15 min and then twice for 5 min. The membrane
was then incubated for 45 min with horseradish peroxidase-conjugated
antirabbit IgG (Santa Cruz Biotechnology, Inc.) diluted
1:2,000 in PBS-T, followed by PBS-T washes, once for 15 min and four
times for 5 min in PBS-T. After the last wash, the membrane was
developed according to manufacturers instructions with a standard ECL
kit (Amersham Pharmacia Biotech, Arlington Heights, IL),
covered with Saran wrap and exposed to x-ray film.
GST-Fusion Proteins
GST-ER(A/B) and GST-cJun (amino acids 179, from Dr. A.
DeFranco, UCSF) fusion protein were prepared as previously described
(86). Briefly, bacteria (500 ml LB media) expressing the fusion
proteins were resuspended in 15 ml of TST buffer (0.5 M
Tris, 1.5 M NaCl, 0.5% Tween 20, pH 7.5) and sonicated
mildly for 23 min in ice. The debris was pelleted at 12,000 rpm for
1 h in an ss34 rotor. The supernatant was rotated gently for
2 h in a cold room with 0.5 ml of glutathione sepharose 4B beads
that had been prewashed with 510 vol of TST buffer. GST-fusion
protein beads were washed with 1020 vol PBS 0.01% Nonidet P-40 and
resuspended in 1:1 vol of 20 mM HEPES, 150 mM
KCl, 5 mM MgCl2, 10% glycerol, 1
mM dithiothreitol, 0.2 mM phenylmethylsulfonyl
fluoride, and protease inhibitors, pH 7.9, for storage at 4 C until
use.
In Vitro Kinase Assay
Src, MAP, and JNK kinase assays were carried out following the
manufacturers protocol (Upstate Biotechnology, Inc.,
Lake Placid, NY) with purified Src, MAP, and JNK kinases, as provided.
Briefly, purified Src, MAP, and JNK kinases were mixed with the
corresponding substrates or GST-ER(A/B), the reaction was started by
adding the corresponding reaction buffer containing
(
-32P)ATP, and then mixed gently and incubated
at 30 C for 1530 min. After addition of 40% trichloroacetic acid or
2x SDS-PAGE loading buffer to stop the reaction, the phosphorylated
kinase substrates and GST-ER(A/B) were detected by liquid scintillation
counter or autoradiography of 1012% SDS-PAGE.
 |
ACKNOWLEDGMENTS
|
---|
We thank David Stokoe for helpful comments on the
manuscript.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Peter Kushner, Metabolic Research Unit 1119 HSW, University of California, San Francisco, CA 94143-0540. E-mail: kushner{at}itsa.ucsf.edu
This work was supported by Public Health Service Grants DK-51083 and
CA-80210 (to P.J.K.) and by grants from the California Breast Cancer
Research Program (to P.J.K. and M.K.).
Peter Kushner wishes to inform readers that he has significant
financial holdings in and is a consultant to KaroBio AB, a
pharmaceutical company with interests in nuclear receptors.
Received for publication April 7, 1999.
Revision received October 5, 2000.
Accepted for publication October 9, 2000.
 |
REFERENCES
|
---|
-
Parker MG 1998 Transcriptional activation by oestrogen
receptors. Biochem Soc Symp 63:4550[Medline]
-
Parker MG 1996 Antiestrogen-estrogen receptor interactions.
Cancer Treat Res 83:213224[Medline]
-
Berry M, Metzger D, Chambon P 1990 Role of the two activating
domains of the oestrogen receptor in the cell-type and promoter-context
dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen.
EMBO J 9:28112818[Abstract]
-
Metzger D, Berry M, Ali S, Chambon P 1995 Effect of
antagonists on DNA binding properties of the human estrogen receptor
in vitro and in vivo. Mol Endocrinol 9:579591[Abstract]
-
McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals
three distinct classes of antiestrogens. Mol Endocrinol 9:659669[Abstract]
-
Glass CK, Rose DW, Rosenfeld MG 1997 Nuclear receptor
coactivators. Curr Opin Cell Biol 9:222232[CrossRef][Medline]
-
Shibata H, Spencer TE, Onate SA, Jenster G, Tsai SY, Tsai MJ,
OMalley BW 1997 Role of co-activators and co-repressors in the
mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 52:141164[Medline]
-
Onate SA, Tsai SY, Tsai MJ, OMalley BW 1995 Sequence and
characterization of a coactivator for the steroid hormone receptor
superfamily. Science 270:13541357[Abstract]
-
Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin
SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG 1996 A CBP integrator
complex mediates transcriptional activation and AP-1 inhibition by
nuclear receptors. Cell 85:403414[Medline]
-
Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR 1996 GRIP1, a novel mouse protein that serves as a transcriptional
coactivator in yeast for the hormone binding domains of steroid
receptors. Proc Natl Acad Sci USA 93:49484952[Abstract/Free Full Text]
-
Voegel JJ, Heine MJS, Zechel C, Chambon P, Gronemeyer H 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent
activation function AF-2 of nuclear receptors. EMBO J 15:36673675[Abstract]
-
Hong H, Kohli K, Garabedian M, Stallcup M 1997 GRIP1, a
transcriptional coactivator for the AF-2 transactivation domain of
steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 17:27352744[Abstract]
-
Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK,
Rosenfeld MG 1997 The transcriptional co-activator p/CIP binds CBP and
mediates nuclear-receptor function. Nature 387:677684[CrossRef][Medline]
-
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan
XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS 1997 AIB1, a steroid
receptor coactivator amplified in breast and ovarian cancer. Science 277:965968[Abstract/Free Full Text]
-
Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L,
Privalsky ML, Nakatani Y, Evans RM 1997 Nuclear receptor coactivator
ACTR is a novel histone acetyltransferase and forms a multimeric
activation complex with P/CAF and CBP/p300. Cell 90:569580[Medline]
-
Li H, Gomes PJ, Chen JD 1997 RAC3, a steroid/nuclear
receptor-associated coactivator that is related to SRC-1 and TIF2. Proc
Natl Acad Sci USA 94:84798484[Abstract/Free Full Text]
-
Takeshita A, Cardona GR, Koibuchi N, Suen CS, Chin WW 1997 TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule,
exhibits distinct properties from steroid receptor coactivator-1.
J Biol Chem 272:2762927634[Abstract/Free Full Text]
-
Chakravarti D, LaMorte V, Nelson M, Nakajima T, Schulman I,
Juguilon H, Montminy M, Evans R 1996 Role of CBP/P300 in nuclear
receptor signalling. Nature 383:99103[CrossRef][Medline]
-
Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B,
Kurokawa R, Brown M 1996 p300 is a component of an estrogen receptor
coactivator complex. Proc Natl Acad Sci USA 93:1154011545[Abstract/Free Full Text]
-
Yao TP, Ku G, Zhou N, Scully R, Livingston DM 1996 The nuclear
hormone receptor coactivator SRC-1 is a specific target of p300. Proc
Natl Acad Sci USA 93:1062610631[Abstract/Free Full Text]
-
Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y 1996 A
p300/CBP-associated factor that competes with the adenoviral
oncoprotein E1A. Nature 382:319324[CrossRef][Medline]
-
Scolnick DM, Chehab NH, Stavridi ES, Lien MC, Caruso L, Moran
E, Berger SL, Halazonetis TD 1997 CREB-binding protein and
p300/CBP-associated factor are transcriptional coactivators of the p53
tumor suppressor protein. Cancer Res 57:36933696[Abstract]
-
Korzus E, Torchia J, Rose DW, Xu L, Kurokawa R, McInerney EM,
Mullen TM, Glass CK, Rosenfeld MG 1998 Transcription factor-specific
requirements for coactivators and their acetyltransferase functions.
Science 279:703707[Abstract/Free Full Text]
-
Webb P, Nguyen P, Shinsako J, Anderson CM, Nguyen MP,
McKinerney E, Katzenellenbogen BS, Stallcup M, Kushner PJ 1998 Estrogen
receptor activation function 1 works by binding p160 coactivator
proteins. Mol Endocrinol 12:16051618[Abstract/Free Full Text]
-
Le DB, Nielsen AL, Garnier JM, Ichinose H, Jeanmougin F,
Losson R, Chambon P 1996 A possible involvement of TIF1
and TIF1ß
in the epigenetic control of transcription by nuclear receptors. EMBO J 15:67016715[Abstract]
-
Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, Gronemeyer H 1998 The coactivator TIF2 contains three nuclear receptor-binding
motifs and mediates transactivation through CBP binding-dependent and
-independent pathways. EMBO J 17:507519[Abstract/Free Full Text]
-
Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature
motif in transcriptional co-activators mediates binding to nuclear
receptors. Nature 387:733736[CrossRef][Medline]
-
Kalkhoven E, Valentine JE, Heery DM, Parker MG 1998 Isoforms
of steroid receptor co-activator 1 differ in their ability to
potentiate transcription by the oestrogen receptor. EMBO J 17:232243[Abstract/Free Full Text]
-
Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ,
Stallcup MR 1998 Nuclear receptor-binding sites of coactivators
glucocorticoid receptor interacting protein 1 (GRIP1) and steroid
receptor coactivator 1 (SRC-1): multiple motifs with different binding
specificities. Mol Endocrinol 12:302313[Abstract/Free Full Text]
-
Bannister AJ, Kouzarides T 1996 The CBP co-activator is a
histone acetyltransferase. Nature 384:641643[CrossRef][Medline]
-
Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y 1996 The transcriptional coactivators p300 and CBP are histone
acetyltransferases. Cell 87:953959[Medline]
-
Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA,
McKenna NJ, Onate SA, Tsai SY, Tsai MJ, OMalley BW 1997 Steroid
receptor coactivator-1 is a histone acetyltransferase. Nature 389:194198[CrossRef][Medline]
-
Ignar-Trowbridge DM, Pimentel M, Teng CT, Korach KS, McLachlan
JA 1995 Cross talk between peptide growth factor and estrogen receptor
signaling systems. Environ Health Perspect 7:3538
-
Ignar-Ttrowbridge DM, Pimentel M, Parker MG, McLachlan JA,
Korach KS 1996 Peptide growth factor cross-talk with the estrogen
receptor requires the A/B domain and occurs independently of protein
kinase C or estradiol. Endocrinology 137:17351744[Abstract]
-
El TM, Green CD 1997 Two separate mechanisms for
ligand-independent activation of the estrogen receptor. Mol Endocrinol 11:928937[Abstract/Free Full Text]
-
Bunone G, Briand PA, Miksicek RJ, Picard D 1996 Activation of
the unliganded estrogen receptor by EGF involves the MAP kinase pathway
and direct phosphor-ylation. EMBO J 15:21742183[Abstract]
-
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H,
Masushige S, Gotoh Y, Nishida E, Kawashima H. Metzger D, Chambon P 1995 Activation of the estrogen receptor through phosphorylation by
mitogen-activated protein kinase. Science 270:14911494[Abstract]
-
Joel PB, Traish AM, Lannigan D 1998 Estradiol-induced
phosphorylation of serine 118 in the estrogen receptor is independent
of p42/p44 mitogen-activated protein kinase. J Biol Chem 273:1331713323[Abstract/Free Full Text]
-
Ali S, Metzger D, Bornert JM, Chambon P 1993 Modulation of
transcriptional activation by ligand-dependent phosphorylation of the
human oestrogen receptor A/B region. EMBO J 12:11531160[Abstract]
-
Le GP, Montano MM, Schodin DJ, Katzenellenbogen BS 1994 Phosphorylation of the human estrogen receptor. Identification of
hormone-regulated sites and examination of their influence on
transcriptional activity. J Biol Chem 269:44584466[Abstract/Free Full Text]
-
Endoh H, Maruyama K, Masuhiro Y, Kobayashi Y, Goto M, Tai H,
Yanagisawa J, Metzger D, Hashimoto S, Kato S 1999 Purification and
identification of p68 RNA helicase acting as a transcriptional
coactivator specific for the activation function 1 of human estrogen
receptor
. Mol Cell Biol 19:53635372[Abstract/Free Full Text]
-
LeMaistre CF, Meneghetti C, Howes L, Osborne CK 1994 Targeting
the EGF receptor in breast cancer treatment. Breast Cancer Res Treat 32:97103[Medline]
-
Chrysogelos SA, Dickson RB 1994 EGF receptor expression,
regulation, and function in breast cancer. Breast Cancer Res Treat 29:2940[Medline]
-
Earp HS, Dawson TL, Li X, Yu H 1995 Heterodimerization and
functional interaction between EGF receptor family members: a new
signaling paradigm with implications for breast cancer research. Breast
Cancer Res Treat 35:115132[Medline]
-
Reese DM, Slamon DJ 1997 HER-2/neu signal transduction in
human breast and ovarian cancer. Stem Cells 15:18[Abstract/Free Full Text]
-
Jacobs C, Rubsamen H 1983 Expression of pp60c-src protein
kinase in adult and fetal human tissue: high activities in some
sarcomas and mammary carcinomas. Cancer Res 43:16961702[Abstract]
-
Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA 1986 Analysis of pp60c-src protein kinase activity in human tumor cell
lines and tissues. J Biol Chem 261:1375413759[Abstract/Free Full Text]
-
Ottenhoff KA, Rijksen G, van Beurden E, Hennipman A, Michels
AA, Staal GE 1992 Characterization of protein tyrosine kinases from
human breast cancer: involvement of the c-src oncogene product. Cancer
Res 52:47734778[Abstract]
-
Verbeek BS, Vroom TM, Adriaansen SS, Ottenhoff KA, Geertzema
JG, Hennipman A, Rijksen G 1996 c-Src protein expression is increased
in human breast cancer. An immunohistochemical and biochemical
analysis. J Pathol 180:383388[CrossRef][Medline]
-
Muthuswamy SK, Muller WJ 1994 Activation of the Src family of
tyrosine kinases in mammary tumorigenesis. Adv Cancer Res 64:111123[Medline]
-
Brown MT, Cooper JA 1996 Regulation, substrates and functions
of src. Biochim Biophys Acta 1287:121149[CrossRef][Medline]
-
Parsons JT, Parsons SJ 1997 Src family protein tyrosine
kinases: cooperating with growth factor and adhesion signaling
pathways. Curr Opin Cell Biol 9:187192[CrossRef][Medline]
-
Thomas SM, Brugge JS 1997 Cellular functions regulated by Src
family kinases. Annu Rev Cell Dev Biol 13:513609[CrossRef][Medline]
-
Xie W, Herschman HR 1995 v-src Induces prostaglandin synthase
2 gene expression by activation of the c-Jun N-terminal kinase and the
c-Jun transcription factor. J Biol Chem 270:2762227628[Abstract/Free Full Text]
-
Brenner B, Weinmann S, Grassme H, Lang F, Linderkamp O,
Gulbins E 1997 L-selectin activates JNK via src-like tyrosine kinases
and the small G-protein Rac. Immunology 92:214219[Medline]
-
Minden A, Lin A, Claret FX, Abo A, Karin M 1995 Selective
activation of the JNK signaling cascade and c-Jun transcriptional
activity by the small GTPases Rac and Cdc42Hs. Cell 81:11471157[Medline]
-
Metzger D, Ali S, Bornert JM, Chambon P 1995 Characterization
of the amino-terminal transcriptional activation function of the human
estrogen receptor in animal and yeast cells. J Biol Chem 270:95359542[Abstract/Free Full Text]
-
Tzukerman MT, Esty A, Santiso MD, Danielian P, Parker MG,
Stein RB, Pike JW, McDonnell DP 1994 Human estrogen receptor
transactivational capacity is determined by both cellular and promoter
context and mediated by two functionally distinct intramolecular
regions. Mol Endocrinol 8:2130[Abstract]
-
McDonnell DP, Dana SL, Hoener PA, Lieberman BA, Imhof MO,
Stein RB 1995 Cellular mechanisms which distinguish between hormone-
and antihormone-activated estrogen receptor. Ann NY Acad Sci 761:121137[Abstract]
-
Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I,
Chambon P 1989 The cloned human oestrogen receptor contains a mutation
which alters its hormone binding properties. EMBO J 8:19811986[Abstract]
-
Arnold SF, Vorojeikina DP, Notides AC 1995 Phosphorylation of
tyrosine 537 on the human estrogen receptor is required for binding to
an estrogen response element. J Biol Chem 270:3020530212[Abstract/Free Full Text]
-
Arnold SF, Melamed M, Vorojeikina DP, Notides AC, Sasson S 1997 Estradiol-binding mechanism and binding capacity of the human
estrogen receptor is regulated by tyrosine phosphorylation. Mol
Endocrinol 11:4853[Abstract/Free Full Text]
-
Auricchio F, Di Domenico M, Migliaccio A, Castoria G, Bilancio
A 1995 The role of estradiol receptor in the proliferative activity of
vanadate on MCF-7 cells. Cell Growth Diff 6:105113[Abstract]
-
White R, Sj
berg M, Kalkhoven E, Parker MG 1997 Ligand-independent activation of the oestrogen receptor by mutation of
a conserved tyrosine. EMBO J 16:14271435[Abstract/Free Full Text]
-
Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS 1996 Constitutively active human estrogen receptors containing amino
acid substitutions for tyrosine 537 in the receptor protein. Mol
Endocrinol 10:13881398[Abstract]
-
Yudt MR, Vorojeikina D, Zhong L, Skafar DF, Sasson S,
Gasiewicz TA, Notides AC 1999 Function of estrogen receptor tyrosine
537 in hormone binding, DNA binding, and transactivation. Biochemistry 38:1414614156[CrossRef][Medline]
-
Berthois Y, Pourreau SN, Gandilhon P, Mittre H, Tubiana N,
Martin PM 1986 Estradiol membrane binding sites on human breast cancer
cell lines. Use of a fluorescent estradiol conjugate to demonstrate
plasma membrane binding systems. J Steroid Biochem 25:963972[CrossRef][Medline]
-
Razandi M, Pedram A, Greene G, Levin E 1999 Cell membrane and
nuclear estrogen receptors (ERs) originate from a single transcript:
studies of ER
and ER ß expressed in Chinese hamster ovary cells.
Mol Endocrinol 13:307319[Abstract/Free Full Text]
-
Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR 1995 PD
098059 is a specific inhibitor of the activation of mitogen-activated
protein kinase kinase in vitro and in vivo.
J Biol Chem 270:2748927494[Abstract/Free Full Text]
-
Lin A, Minden A, Martinetto H, Claret FX, Lange-Carter C,
Mercurio F, Johnson GL, Karin M 1995 Identification of a dual
specificity kinase that activates the Jun kinases and p38-Mpk2. Science 268:286290[Medline]
-
Webb P, Nguyen P, Valentine C, Lopez G, Kwok GR, McInerney E,
Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, Kushner PJ 1999 The estrogen receptor enhances AP-1 activity by two distinct
mechanisms with different requirements for receptor transactivation
functions. Mol Endocrinol 13:16721685[Abstract/Free Full Text]
-
McInerney EM, Katzenellenbogen BS 1996 Different regions in
activation function-1 of the human estrogen receptor required for
antiestrogen- and estradiol-dependent transcription activation. J
Biol Chem 271:2417224178[Abstract/Free Full Text]
-
Lin A, Smeal T, Binetruy B, Deng T, Chambard JC, Karin M 1993 Control of AP-1 activity by signal transduction cascades. Adv Second
Messenger Phosphoprotein Res 28:255260[Medline]
-
Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M 1991 Oncogenic and transcriptional cooperation with Ha-Ras requires
phosphorylation of c-Jun on serines 63 and 73. Nature 354:494496[CrossRef][Medline]
-
Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M,
Davis RJ 1994 JNK1: a protein kinase stimulated by UV light and Ha-Ras
that binds and phosphorylates the c-Jun activation domain. Cell 76:10251037[Medline]
-
Cavigelli M, Dolfi F, Claret FX, Karin M 1995 Induction of
c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J 14:59575964[Abstract]
-
Hibi M, Lin A, Smeal T, Minden A, Karin M 1993 Identification
of an oncoprotein- and UV-responsive protein kinase that binds and
potentiates the c-Jun activation domain. Genes Dev 7:21352148[Abstract]
-
Kallunki T, Deng T, Hibi M, Karin M 1996 c-Jun can recruit JNK
to phosphorylate dimerization partners via specific docking
interactions. Cell 87:929939[Medline]
-
Ma H, Hong H, Huang SM, Irvine RA, Webb P, Kushner PJ, Coetzee
GA, Stallcup MR 1999 Multiple signal input and output domains of the
160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol 19:61646173[Abstract/Free Full Text]
-
Clark JW, Santos MA, Stevenson LE, Frackelton AJ 1996 Effects
of tyrosine kinase inhibitors on the proliferation of human breast
cancer cell lines and proteins important in the ras signaling pathway.
Int J Cancer 65:186191[CrossRef][Medline]
-
Hoffman R 1995 Potent inhibition of breast cancer cell lines
by the isoflavonoid kievitone: comparison with genistein. Biochem
Biophys Res Commun 211:600606[CrossRef][Medline]
-
Panno ML, Salerno M, Pezzi V, Sisci D, Maggiolini M, Mauro L,
Morrone EG, Ando S 1996 Effect of oestradiol and insulin on the
proliferative pattern and on oestrogen and progesterone receptor
contents in MCF-7 cells. J Cancer Res Clin Oncol 122:745749[Medline]
-
Peterson G, Barnes S 1996 Genistein inhibits both estrogen and
growth factor-stimulated proliferation of human breast cancer cells.
Cell Growth Differ 7:13451351[Abstract]
-
Webb P, Lopez GN, Greene GL, Baxter JD, Kushner PJ 1992 The
limits of the cellular capacity to mediate an estrogen response. Mol
Endocrinol 6:157167[Abstract]
-
Saatcioglu F, Lopez G, West BL, Zandi E, Feng W, Lu H, Esmaili
A, Apriletti JW, Kushner PJ, Baxter JD, Karin M 1997 Mutations in the
conserved C-terminal sequence in thyroid hormone receptor dissociate
hormone-dependent activation from interference with AP-1 activity. Mol
Cell Biol 17:46874695[Abstract]
-
Webb P, Lopez GN, Uht RM, Kushner PJ 1995 Tamoxifen activation
of the estrogen receptor/AP-1 pathway: potential origin for the
cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9:443456[Abstract]
-
Sadovsky Y, Webb P, Lopez G, Baxter JD, Fitzpatrick PM, Gizang
GE, Cavailles V, Parker MG, Kushner PJ 1995 Transcriptional activators
differ in their responses to overexpression of TATA-box-binding
protein. Mol Cell Biol 15:15541563[Abstract]